The fresh capital will be used to expand Sugar.fit’s product offering, launch an offline presence and accelerate research and development in the field of diabetes management, accelerating the brand’s footprint and growth
Read More
Despite the decline in deal volume, there was a significant surge of 298 per cent in deal values year-on-year, mainly attributed to two high-value deals, each valued at over USD 650 million, and an additional four deals valued over USD 100 million each
Read More
Strides Pharma Science disclosed a consolidated net loss of Rs 149 crore for the second quarter concluding on September 30, 2023. This marks a stark contrast to the net profit of Rs 19 crore reported during the same period the previous year
Read More
The addition of KIMSHEALTH to the CARE Hospitals network creates one of India’s largest hospital platforms with 23 facilities across 11 cities in India, creating a leadership position in under-penetrated, emerging cities that have strong potential for growth
Read More
Strides has emphasised that this transaction will be EPS (earnings per share) accretive and will not impact the company's revenues
Read More
Piramal Pharma's bottomline finally turned green this quarter with Rs 5 crore profit after tax (PAT) against a loss of Rs 37 crore in Q2FY23 and Rs 99 crore loss in Q1FY24
Read More
Cipla's net profit jumped by a whopping 43.4 per cent year on year (YoY) in Q2FY24, the company recorded a net profit of Rs 1,131 crores in the September quarter. The company saw an increase of Rs 342 crores from the earnings of the same quarter last year which stood at Rs 789 crores.
Read More
In FY 22-23 reported a gross written premium of Rs150+ Crore in Andhra Pradesh and Telangana
Read More
